Taft Pharma Litigation Practice “Recommended” by LMG Life Sciences
Taft’s Pharmaceutical & Life Sciences Litigation practice has been “Recommended” in the area of Hatch-Waxman Patent Litigation (Generic) by the LMG Life Sciences Awards. Group chair Steve Auten was also one of six attorneys nominated in the category “Hatch-Waxman Litigator of the Year-Generic.”
Now in its sixth year, the LMG Life Sciences Awards recognize key law firms, lawyers, and the innovative work being accomplished throughout the life sciences industry. The awards were given out at a ceremony on Sept. 12 in New York.
Auten is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog “Hatch Waxman ANDA Litigation Forum,” which has more than 8,600 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.
In This Article
You May Also Like
Auten and Shannon Contribute Chapter on Hatch-Waxman and BPCIA Litigation to Biosimilars Litigation Book Powell Joins Taft’s IP Group